HOWL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Werewolf Therapeutics Inc (HOWL) is not a good buy for a beginner investor with a long-term strategy at this time. The stock shows weak technical indicators, significant financial challenges, and a lack of positive catalysts. Analysts have downgraded the stock, citing cash constraints and uncertain strategic partnerships. Additionally, hedge funds are selling, and there is no recent congress trading data or positive news to support a bullish sentiment.
The stock's MACD is negative and contracting, RSI is neutral, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with resistance at 0.708 and support at 0.561. Overall, the technical indicators suggest a bearish trend.
No significant positive catalysts identified. The company has shown some clinical activity in its pipeline, but these are overshadowed by financial and strategic challenges.
Hedge funds are selling heavily, analysts have downgraded the stock citing cash constraints and uncertain timing of strategic partnerships, and the company's financial performance shows no revenue growth and worsening net income and EPS.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income drop to -$16.37M (-1.82% YoY), and an EPS decline to -0.36 (-5.26% YoY). Gross margin dropped to 0, down 100% YoY. The financials indicate significant challenges.
Analysts have downgraded the stock. H.C. Wainwright lowered its price target to $4 from $10 but maintained a Buy rating. Wedbush downgraded the stock to Neutral from Outperform with a price target of $1, citing cash constraints and strategic uncertainties. Citizens also downgraded the stock to Market Perform, citing the need for a strategic partner or additional funding.
